Who is sponsoring NCT03686605?

NCT03686605 is sponsored by Mahidol University.

What drugs are being tested in NCT03686605?

Interventions in NCT03686605: Thai version of the Edmontom Symptom Assessment System (ESAS).

What condition does NCT03686605 study?

NCT03686605 studies Screening Tool for Depresion in Cancer Pain Patients.

Is NCT03686605 still recruiting?

NCT03686605 is currently completed. Last updated 28 July 2022.

Last reviewed 2022-07-28 · How we verify

NCT03686605

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Edmonton Symptom Assessment System (ESAS) as a Screening Tool for Depression in Cancer Pain Patients

Completed Last updated 28 July 2022

What this trial tests

trial testing Thai version of the Edmontom Symptom Assessment System (ESAS) in Screening Tool for Depresion in Cancer Pain Patients in 49 participants. Completed in 31 January 2020.

Timeline

24 September 2018

Primary endpoint
31 December 2019

31 January 2020

Quick facts

Lead sponsor	Mahidol University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	49
Start date	24 September 2018
Primary completion	31 December 2019
Estimated completion	31 January 2020
Sites	1 location across Thailand

Drugs / interventions tested

Thai version of the Edmontom Symptom Assessment System (ESAS)

Conditions studied

Screening Tool for Depresion in Cancer Pain Patients — all drugs for Screening Tool for Depresion in Cancer Pain Patients →

Sponsor

Mahidol University

Who can join

18 and older, any sex, with Screening Tool for Depresion in Cancer Pain Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Compare Thai versions of the Edmonton Symptom Assessment System (ESAS) and the Hospiral Anxiety and Depression Scale (HADS) with Diagnostic and Statistical Manual (DSM-5), as a screening tool for depression in cancer pain patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Mahidol University trials

Trials by the same sponsor.

NCT07568496 — Greater Occipital Nerve Block for Migraine With Medication Overuse Headache · NA · not yet recruiting
NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
NCT07378501 — Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study · not yet recruiting
NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
NCT07390006 — Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03686605 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mahidol University
Last refreshed: 28 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03686605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing